Navigation Links
UTSA wins San Antonio Area Foundation grant to further chlamydia research
Date:6/23/2009

San Antonio Ashlesh Murthy, the newest research assistant professor in the South Texas Center for Emerging Infectious Diseases (STCEID) at The University of Texas at San Antonio (UTSA), has received a $32,000 grant from the Semp Russ Foundation of the San Antonio Area Foundation to study the role of CD8-positive T-cells in chlamydia infections. Chlamydia, caused by the bacterium Chlamydia trachomatis, is the nation's most common bacterial sexually transmitted disease.

Nearly 2.8 million new chlamydia cases are reported each year in the United States, according to the Centers for Disease Control and Prevention; the disease is most prevalent among teen girls. The infection rate in Texas is slightly higher than the national average. Nearly 17% of Texas females in the 15-19 age group test positive for the infection.

However, experts believe even more chlamydia cases exist than are reported, because the disease generally progresses without exhibiting noticeable symptoms. Left untreated, chlamydia infections can do severe damage in women, causing ectopic pregnancies, pelvic inflammatory disease and even infertility. In men, complications can occur but are generally less severe.

Murthy, a practicing physician from India, entered the Ph.D. program in cellular and molecular biology (CMB) at UTSA in 2002. Working alongside Bernard Arulanandam, professor of microbiology and immunology in UTSA's Department of Biology, Murthy has conducted significant chlamydia research, resulting in findings that have been presented both nationally and internationally by UTSA's chlamydia team.

In 2006, Murthy earned his Ph.D., the first CMB Ph.D. degree awarded by the university. Thereafter, he completed two years of post-doctoral research in UTSA's infectious disease center. Recently, he joined UTSA's Department of Biology as a research assistant professor. The San Antonio Area Foundation award is Murthy's first funding as principal investigat
'/>"/>

Contact: Christi Fish
christi.fish@utsa.edu
210-458-7584
University of Texas at San Antonio
Source:Eurekalert

Page: 1 2

Related biology news :

1. Animal and biological science highlights: San Antonio Fluid Dynamics Conference, Nov. 23-25
2. CTRC-AACR San Antonio Breast Cancer Symposium
3. 31st Annual San Antonio Breast Cancer Symposium
4. The BBVA Foundation presents its Frontiers of Knowledge Awards
5. Five outstanding young gastroenterologists receive AGA Foundation 2009 Research Scholars Award
6. Society of Interventional Radiology Foundation awards $191,000 in grants
7. The evolutionary foundation of genomic imprinting in lower vertebrates
8. UC Davis bioengineer receives Hartwell Foundation grant to address skull fusion disorder of infants
9. G. Unger Vetlesen Foundation funds purchase of state-of-the-art equipment for UMs Rosenstiel School
10. $10 million Simons Foundation gift supports new initiative with Institute for Advanced Study
11. Innerscope Research(R) Receives Three Great Minds Innovation Awards from the Advertising Research Foundation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/8/2015)... July 8, 2015  Trovagene, Inc. (NASDAQ: ... today announced the launch of a study that ... Cancer Monitoring℠ (PCM) technology for predicting response to ... a combination of the novel immunotherapy agents Yervoy® ... PD-1 inhibitor. The 50-patient study will be led ...
(Date:7/7/2015)... MOUNTAIN VIEW, Calif. , July 7, 2015 ... mobile biometrics market, Frost & Sullivan recognizes Credence ... & Sullivan Entrepreneurial Company of the Year ... product suite to aid in its mission of ... and under-recognized populations globally. As Credence ID was ...
(Date:7/2/2015)... , June 25, 2015 ... of the "Next Generation Biometrics Market by Application, ... report to their offering. The next ... by 2020, at a CAGR of 17.9% between 2015 ... leading application for the market. Safran SA ...
Breaking Biology News(10 mins):Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 2Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 5Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 2Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 3
... 2012) -- Dr. Darja Marolt, an Investigator at The New ... a study showing that human embryonic stem cells can be ... and potential therapeutic application. Dr. Marolt conducted this research as ... the laboratory of Dr. Gordana Vunjak-Novakovic. The study ...
... "Weather Islands" off the west coast of Sweden. It ... in Sweden. Lars-Ove Loo is the underwater photographer who has ... inventory ahead of the creation of a new nature reserve in ... surface of the sea south of Lyng in the southern Vderarna ...
... 14, 2012) -- Water could change the way we eat. ... Cornwell of the University of Oregon and Anna R. McAlister ... ahead of regular publication by the journal Appetite . ... of 60 young U.S. adults (ages 19-23) about the role ...
Cached Biology News:Begin early: Researchers say water with meals may encourage wiser choices 2
(Date:7/30/2015)... --  Senomyx , Inc. (NASDAQ: SNMX ), a ... develop, and commercialize novel flavor ingredients for the food, ... for the second quarter 2015. "Moving ... track to achieve our commercial and financial goals," stated ... Company. "Since our last quarterly earnings report, our two ...
(Date:7/30/2015)... 2015 Ascendis Pharma A/S (Nasdaq: ... innovative TransCon technology to address significant unmet medical ... six-month Phase 2 study to evaluate the safety ... 53 treatment-naïve, pre-pubertal children with growth hormone deficiency, ... with the top-line results from our Phase 2 ...
(Date:7/30/2015)...  Discovery Laboratories, Inc. (Nasdaq: DSCO ) ... $1.0M tranche under a previously awarded Phase II ... up to $3.0 million to support continued development ... potential medical countermeasure to mitigate acute and chronic/late-phase ... initial $1.0 million under this grant in October ...
(Date:7/30/2015)... ... 30, 2015 , ... GEA's Pony™ NS2006L is ... up to 1500 bar. The sanitary design gauge of the NS2006L is well ... The Pony™ NS2006L homogenizer is an ideal solution for the processing of ...
Breaking Biology Technology:SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 2SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 3SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 4SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 5SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 6SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 7SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 8SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 9Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 2Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 3GEA Announces the Pony™ NS2006L… a Self-contained, High Pressure Lab Homogenizer for Product Development Ensuring Maximum Efficiency and Safety 2
... Copper,s days are numbered, and a new study ... the ubiquitous metal in smart phones, tablet computers, and ... who are seeking smaller, faster devices. As ... size, so do the copper pathways that transport electricity ...
... Interleukin Genetics, Inc. (OTCQB: ILIU) today announced financial and ... Total revenue for the three months ended September ... period in the prior year. The increase was attributable to ... expenses were $325,000 for the three months ended September 30, ...
... Nov. 10, 2011 GeoVax Labs, Inc. (OTCQB/OTCBB: GOVX), ... prevent and fight Human Immunodeficiency Virus (HIV) infections, today ... September 30, 2011. GeoVax reported a net ... months ended September 30, 2011, compared to $644,666 ($0.04 ...
Cached Biology Technology:Researching graphene nanoelectronics for a post-silicon world 2Researching graphene nanoelectronics for a post-silicon world 3Interleukin Genetics Reports Third Quarter 2011 Financial Results 2Interleukin Genetics Reports Third Quarter 2011 Financial Results 3Interleukin Genetics Reports Third Quarter 2011 Financial Results 4GeoVax Labs, Inc. Announces Nine Month 2011 Financial Results 2GeoVax Labs, Inc. Announces Nine Month 2011 Financial Results 3GeoVax Labs, Inc. Announces Nine Month 2011 Financial Results 4GeoVax Labs, Inc. Announces Nine Month 2011 Financial Results 5
Alexa Fluor 647 anti-mouse Qa-2...
Mouse monoclonal [0.T.81] to Lac1 ( Abpromise for all tested applications). Antigen: Recombinant TrpE fusion protein containing full length E. coli Lac1....
normal human fibroblasts Source: Cell Lysate Form: Ready to Use Application: Western Blotting Control...
Madin-Darby bovine kidney (MDBK) cells Source: Cell Lysate Form: Ready to Use Application: Western Blotting Control...
Biology Products: